ANASTIM study: ANastim (Neoruscine, Tocopherol nicotinate, GP4G and Biotin) Assessment of Safety and Tolerability In Management of Hairloss

Abbott Healthcare Pvt Ltd0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Healthy male and female subjects who are 18 to 40 years of age.
•2.Patients with hair loss disorders such as telogen effluvium (as first line therapy), chronic female pattern hair loss, Androgenetic Alopecia (Stage I â?? IV) (as combination with minoxidil)
•3.Site involved - scalp

•1.Androgenetic alopecia (Stage V and beyond)
•2.Evidence of dermatological disease as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication
•3.Current use of dermatological drugs / preparations which may interfere with study evaluation
•4.Intolerance to any of ingredients of the formulation
•5.Current alcohol or drug abuse
•6.Subjects viewed by the investigator as not being able to complete the study.
•7.Hair product such as hair dyes, sprays, setting gels and restorers
•8.Any procedures for hair enhancement and curling or straightening techniques
•9.Pregnant or breastfeeding women
•10.Patient or having participated in a clinical trial in the month before

发起方